Adapting LFI for Melioidosis

Sponsor
Duke University (Other)
Overall Status
Completed
CT.gov ID
NCT03528265
Collaborator
(none)
100
1
6.6
15.1

Study Details

Study Description

Brief Summary

Towards the goal of reducing melioidosis, this study will help clinicians in Sarawak to diagnose and understand the causes and risk factors for melioidosis. The data will help the clinicians to provide faster test results and better clinical care. The investigator's laboratory efforts will supplement available diagnostics by adding a new, easier-to-use test involving lateral flow immunoassay to rapidly detect Burkholderia pseudomallei, a bacterium causing melioidosis. The study aims to study up to 400 patients with melioidosis-like symptoms who are admitted to Kapit Hospital, Sarawak, Malaysia. No participants will be enrolled from other sites. The study will also examine the demographic, behavioral and occupational risk factors associated with hospital admissions to understand any existing associations between these variables and melioidosis prevalence.

Condition or Disease Intervention/Treatment Phase
  • Device: Lateral flow immunoassay

Study Design

Study Type:
Observational
Actual Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Adapting a Rapid Lateral Flow Burkholderia Pseudomallei Immunoassay in Sarawak, Malaysia
Actual Study Start Date :
Jun 21, 2018
Actual Primary Completion Date :
Jan 8, 2019
Actual Study Completion Date :
Jan 8, 2019

Arms and Interventions

Arm Intervention/Treatment
Patients with melioidosis-like symptoms admitted to Kapit Hosp

Device: Lateral flow immunoassay
Biospecimens of patients with melioidosis-like symptoms will be tested with lateral flow immunoassay to detect Burkholderia pseudomallei, bacterium causing melioidosis

Outcome Measures

Primary Outcome Measures

  1. Proportion of true positive [up to 5 weeks]

    Proportion of true positive of Bukholderia pseudomallei using rapid diagnostic tests compared to the results of qPCR, bacterial culture and Gram stain

  2. Proportion of true negative [up to 5 weeks]

    Proportion of true negative of Bukholderia pseudomallei using rapid diagnostic tests compared to the results of qPCR, bacterial culture and Gram stain

Secondary Outcome Measures

  1. Statistical association between risk factors and test results [up to 3 months]

    conduct a survey to determine a statistical association between clinical risk factors and the test results combined

Eligibility Criteria

Criteria

Ages Eligible for Study:
6 Months and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Admitted to Kapit Hospital

  • Fever more than 3 days and one or more of the following:

  • Enlarged cervical, inguinal or axillary lymph nodes (greater than 3 cm in diameter), painless adenopathy or lymphadenitis or lymph node abscesses

  • One or both sides glands involvement such as tender swelling over medial aspect of the lower eyelid of the lacrimal glands; submandibular glands, parotic glands

  • Bedside scan with splenic or liver hypoechoic lesion (less than 2cm in diameter)

  • Pneumonia not responding to 48 hours of first line antibiotics

  • One or more joint pain with swelling

  • Purplish vesicle or bullae mainly over the lower limbs, may resulting in ulcer after rupture

  • Deep seated abscess or brain abscess or genitourinary abscess or osteomyelitis

  • Severe sepsis patient with or without shock and/or with multiorgan involvement

Exclusion Criteria:
  • Have a clear alternative diagnosis other than melioidosis by a trained health care professional at the Kapit Hospital

  • Have already been treated for melioidosis (e.g. received antibiotics before the start of the study)

  • Are younger than 6 months of age

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kapit Hospital Kapit Sarawak Malaysia

Sponsors and Collaborators

  • Duke University

Investigators

  • Principal Investigator: Gregory C Gray, MD, MPH, Duke University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Duke University
ClinicalTrials.gov Identifier:
NCT03528265
Other Study ID Numbers:
  • Pro00091842
First Posted:
May 17, 2018
Last Update Posted:
Aug 1, 2019
Last Verified:
Jul 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by Duke University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 1, 2019